IP Library Granted Patent US 11,118,230
Granted Patent B2
US 11,118,230 · App. 16/013,240 · Granted Sep 14, 2021

Compositions and methods for performing methylation detection assays

Inventors: David Alan Ahlquist (Rochester, MN); William Russell Taylor (Lake City, MN); Douglas W. Mahoney (Rochester, MN); Graham P. Lidgard (Middelton, WI); Hatim T. Allawi (Middeton, WI); Abram Michael Vaccaro (Rio, WI)
Assignees: Exact Sciences Development Company, LLC; Mayo Foundation for Medical Education and Research
C12Q1/6886C12Q2600/154C12Q2600/156C12Q2600/166
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,118,230
App. No.
16/013,240
Granted
Sep 14, 2021
Kind
B2
Abstract

Provided herein is technology relating to performing methylation assays. In particular, the technology relates to internal controls for methylation assays.

Claims (12)

1. A composition, comprising:

a) a complex of a bisulfite-treated ZDHHC1 DNA comprising SEQ ID NO:33 or its complement, and at least one oligonucleotide complementary to SEQ ID NO:33 or its complement, wherein said oligonucleotide is specifically hybridized to a site in said bisulfite-treated ZDHHC1 DNA within SEQ ID NO:33 or its complement, wherein the at least one oligonucleotide complementary to SEQ ID NO:33 or its complement is a detection probe oligonucleotide; and

b) complexes of two to seven marker DNAs selected from the group consisting of vimentin, septin 9, NDRG4, BMP3, VAV3, SFMBT2, and TFPI2a, and oligonucleotides specifically hybridized to the marker DNAs;

wherein the complexes are in one or more reaction mixtures that each comprise one or more of a FRET cassette and a FEN-1 endonuclease.

2. The composition of claim 1 , wherein said oligonucleotides specifically hybridized to the two to seven marker DNAs are selected from one or more of a capture oligonucleotide, a pair of nucleic acid primers, a probe oligonucleotide, and an invasive oligonucleotide.

3. The composition of claim 1 , in a reaction mixture with one or more nucleic acids selected from the group consisting of: oligonucleotides of SEQ ID NOS:8-10, 52, 56-60, and 63-65, a strand of DNA comprising the nucleotide sequence of SEQ ID NO:54, a strand of DNA comprising the nucleotide sequence of SEQ ID NO:61, and a strand of DNA comprising the nucleotide sequence of SEQ ID NO: 68.

4. The composition of claim 1 , wherein said detection probe oligonucleotide comprises a reporter molecule.

5. The composition of claim 4 , where said reporter molecule comprises a fluorophore.

6. The composition of claim 1 , wherein said detection probe oligonucleotide comprises a flap sequence.

7. The composition of claim 1 , further comprising a thermostable DNA polymerase.

8. The composition of claim 1 , wherein the two to seven marker DNAs are bisulfate-treated genomic DNAs.

9. The composition of claim 1 , wherein a reaction mixture comprising the complex of a bisulfate-treated ZDHHC1 DNA comprising SEQ ID NO:33 or its complement and the at least one oligonucleotide complementary to SEQ ID NO:33 or its complement does not contain said complexes of two to seven marker DNAs.

Assignments (2)
PATENT SECURITY AGREEMENT Recorded Jan 14, 2025
From: EXACT SCIENCES CORPORATION
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 069898/0249 →
MERGER Recorded Jan 14, 2022
From: EXACT SCIENCES DEVELOPMENT COMPANY, LLC
To: EXACT SCIENCES CORPORATION
Reel/Frame 058738/0465 →